Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma.
Hamamoto S, Tasaki Y, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Sugiyama Y, Taguchi K, Yasui T. Hamamoto S, et al. Among authors: fujita k. Front Oncol. 2024 Sep 2;14:1400041. doi: 10.3389/fonc.2024.1400041. eCollection 2024. Front Oncol. 2024. PMID: 39286026 Free PMC article.
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group. Matsushita Y, et al. Among authors: fujita k. Int J Urol. 2024 May;31(5):526-533. doi: 10.1111/iju.15396. Epub 2024 Jan 19. Int J Urol. 2024. PMID: 38240169
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T. Sazuka T, et al. Among authors: fujita k. Sci Rep. 2023 Nov 23;13(1):20629. doi: 10.1038/s41598-023-48087-4. Sci Rep. 2023. PMID: 37996622 Free PMC article.
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.
Matsumura N, Fujita K, Nishimoto M, Yamamoto Y, Kuwahara K, Nagai Y, Minami T, Hatanaka Y, Nozawa M, Morimoto Y, Tahara H, Uejima S, Esa A, Hirayama A, Yoshimura K, Uemura H. Matsumura N, et al. Among authors: fujita k. Front Oncol. 2021 Dec 21;11:769068. doi: 10.3389/fonc.2021.769068. eCollection 2021. Front Oncol. 2021. PMID: 34993133 Free PMC article.
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N. Kato T, et al. Among authors: fujita k. Int J Clin Oncol. 2022 Oct;27(10):1596-1604. doi: 10.1007/s10147-022-02215-8. Epub 2022 Jul 13. Int J Clin Oncol. 2022. PMID: 35831538
Genomic and Pathological Characterization of Multiple Renal Cell Carcinoma Regions in Patient With Tuberous Sclerosis Complex: A Case Report.
Yamamoto T, Kato T, Hatano K, Kawashima A, Ujike T, Fukuhara S, Kiuchi H, Imamura R, Ibuki N, Kiyotani K, Kurashige M, Morii E, Fujita K, Nonomura N, Uemura M. Yamamoto T, et al. Among authors: fujita k. Front Oncol. 2021 May 12;11:691996. doi: 10.3389/fonc.2021.691996. eCollection 2021. Front Oncol. 2021. PMID: 34055654 Free PMC article.
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Hashimoto M, Nakayama T, Fujimoto S, Inoguchi S, Nishimoto M, Kikuchi T, Adomi S, Banno E, De Velasco MA, Saito Y, Shimizu N, Mori Y, Minami T, Fujita K, Nozawa M, Nose K, Yoshimura K, Uemura H. Hashimoto M, et al. Among authors: fujita k. Anticancer Drugs. 2022 Jan 1;33(1):e818-e821. doi: 10.1097/CAD.0000000000001230. Anticancer Drugs. 2022. PMID: 34486537
5,143 results